DE69916073D1 - Triazolopyridine für behandlung von thrombosen - Google Patents

Triazolopyridine für behandlung von thrombosen

Info

Publication number
DE69916073D1
DE69916073D1 DE69916073T DE69916073T DE69916073D1 DE 69916073 D1 DE69916073 D1 DE 69916073D1 DE 69916073 T DE69916073 T DE 69916073T DE 69916073 T DE69916073 T DE 69916073T DE 69916073 D1 DE69916073 D1 DE 69916073D1
Authority
DE
Germany
Prior art keywords
triazolopyridine
thromboses
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69916073T
Other languages
English (en)
Other versions
DE69916073T2 (de
Inventor
J Hoekstra
C Lawson
E Maryanoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Publication of DE69916073D1 publication Critical patent/DE69916073D1/de
Application granted granted Critical
Publication of DE69916073T2 publication Critical patent/DE69916073T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
DE69916073T 1998-07-27 1999-07-21 Triazolopyridine für behandlung von thrombosen Expired - Fee Related DE69916073T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9423198P 1998-07-27 1998-07-27
US94231P 1998-07-27
US354032 1999-07-15
US09/354,032 US6303625B1 (en) 1998-07-27 1999-07-15 Triazolopyridines for the treatment of thrombosis disorders
PCT/US1999/016572 WO2000006570A1 (en) 1998-07-27 1999-07-21 Triazolopyridines for the treatment of thrombosis disorders

Publications (2)

Publication Number Publication Date
DE69916073D1 true DE69916073D1 (de) 2004-05-06
DE69916073T2 DE69916073T2 (de) 2004-12-30

Family

ID=22243910

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69916073T Expired - Fee Related DE69916073T2 (de) 1998-07-27 1999-07-21 Triazolopyridine für behandlung von thrombosen

Country Status (21)

Country Link
US (1) US6303625B1 (de)
EP (1) EP1102766B1 (de)
JP (1) JP2003527306A (de)
KR (1) KR20010079576A (de)
CN (1) CN1320125A (de)
AR (1) AR019477A1 (de)
AT (1) ATE263169T1 (de)
AU (1) AU757512B2 (de)
BR (1) BR9912556A (de)
CA (1) CA2338654A1 (de)
CZ (1) CZ2001347A3 (de)
DE (1) DE69916073T2 (de)
ES (1) ES2219042T3 (de)
HU (1) HUP0103832A3 (de)
ID (1) ID27214A (de)
MX (1) MXPA01001099A (de)
NO (1) NO20010456L (de)
PL (1) PL345769A1 (de)
SK (1) SK1342001A3 (de)
WO (1) WO2000006570A1 (de)
ZA (1) ZA200100783B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306909B1 (en) 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
CZ2002518A3 (cs) * 1999-08-13 2002-05-15 Biogen, Inc. Inhibitory buněčné adheze a farmaceutické prostředky, které je obsahují
TWI290136B (en) * 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
JP2004536071A (ja) * 2001-05-25 2004-12-02 クイーンズ ユニバーシティ アット キングストン 複素環ベータアミノ酸およびそれらの抗癲癇誘発剤としての使用
WO2003000657A1 (fr) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Derives de diamine
WO2006018727A2 (en) * 2004-08-18 2006-02-23 Pharmacia & Upjohn Company Llc Triazolopyridine compounds useful for the treatment of inflammation
US7618983B2 (en) * 2004-11-10 2009-11-17 Janssen Pharmaceutica, N.V. Bicyclic triazole α4 integrin inhibitors
HUE029336T2 (en) * 2005-09-16 2017-02-28 Daiichi Sankyo Co Ltd For the preparation of an optically active diamine derivative and process
WO2008045393A2 (en) * 2006-10-11 2008-04-17 Amgen Inc. Imidazo- and triazolo-pyridine compounds and methods of use therof
EP2417135A1 (de) * 2009-04-07 2012-02-15 Schering Corporation Substituierte triazolopyridine und analoga davon
US8871760B2 (en) * 2009-09-21 2014-10-28 Roche Palo Alto Llc [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators
MX339302B (es) 2011-09-15 2016-05-19 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
EP3004095A1 (de) * 2013-06-03 2016-04-13 Bayer Pharma Aktiengesellschaft Triazolopyridine als thrombininhibitoren zur behandlung von thromboembolischen erkrankungen
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3050525A (en) 1960-12-14 1962-08-21 John B Bicking Certain derivatives of s-triazolo [4, 3-a]-pyridine
NZ262664A (en) 1993-02-22 1997-04-24 Merck & Co Inc Heterocyclic substituted derivatives, and medicaments thereof
DE4326758A1 (de) * 1993-08-10 1995-02-16 Basf Ag [1,3,4]Triazolo[1,5-a]pyridine
CA2134192A1 (en) 1993-11-12 1995-05-13 Michael L. Denney 5, 6-bicyclic glycoprotein iib/iiia antagonists

Also Published As

Publication number Publication date
JP2003527306A (ja) 2003-09-16
EP1102766A1 (de) 2001-05-30
WO2000006570A1 (en) 2000-02-10
ES2219042T3 (es) 2004-11-16
AU5221899A (en) 2000-02-21
PL345769A1 (en) 2002-01-02
HUP0103832A3 (en) 2002-12-28
CZ2001347A3 (cs) 2001-12-12
HUP0103832A2 (hu) 2002-04-29
US6303625B1 (en) 2001-10-16
ZA200100783B (en) 2002-01-28
NO20010456D0 (no) 2001-01-26
SK1342001A3 (en) 2002-04-04
ID27214A (id) 2001-03-08
NO20010456L (no) 2001-03-26
CN1320125A (zh) 2001-10-31
DE69916073T2 (de) 2004-12-30
CA2338654A1 (en) 2000-02-10
AR019477A1 (es) 2002-02-20
AU757512B2 (en) 2003-02-20
ATE263169T1 (de) 2004-04-15
MXPA01001099A (es) 2002-04-24
EP1102766B1 (de) 2004-03-31
KR20010079576A (ko) 2001-08-22
BR9912556A (pt) 2002-01-15

Similar Documents

Publication Publication Date Title
DE69925306D1 (de) Behandlung von kohlenwasserstoffgas
ATE300597T1 (de) Behandlung von geweben
DE69927823D1 (de) Hydrogel für die therapeutische behandlung von aneurysmas
DE60001421D1 (de) Behandlung von abgas
ATE260332T1 (de) Behandlung von textilien
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE69806579T2 (de) Anlage zur behandlung von nahrungsmitteln
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
ID27191A (id) Metode untuk pengobatan insomnia
ATE291427T1 (de) Verwendung von optisch reinem (+)-norcisapride für die behandlung des reizdarmsyndroms
ATE266082T1 (de) Behandlung von substratoberfläche
DE69916073D1 (de) Triazolopyridine für behandlung von thrombosen
DE60014928D1 (de) Retinoide zur behandlung von emphysem
ATE263777T1 (de) Zusammensetzungen zur behandlung von entzündungsreaktionen
DE69501172T2 (de) Einrichtung für die Behandlung von Substrat
DE60031790D1 (de) Rar-gamma selektive retinoid-agonisten zur behandlung von emphysemen
DE69835419D1 (de) Verfahren zur Behandlung von organischem Abwasser
DE69943089D1 (de) Methode zur behandlung von staphylokokkeninfektionen
DE69932235D1 (de) Behandlung von herzhypertrophie
DE69900339T2 (de) Mittel und Verfahren zur Behandlung von Kunstfasern
DE69905214T2 (de) Mittel zur Behandlung der Osteoporose
DE69926485D1 (de) Behandlung von durchblasgasen
ATE230741T1 (de) 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen
PT1051172E (pt) Metodo para tratamento da dpco
DE60021521D1 (de) Isonipecotamide zur behandlung von integrin vermittelten störungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: BOEHMERT & BOEHMERT, 28209 BREMEN

8339 Ceased/non-payment of the annual fee